Atara Biotherapeutics cuts 50% of workforce, discontinues two CAR T programs

Atara Biotherapeutics, Inc.

Reducing workforce by ~50%; expected to substantially complete by June 2025.
Discontinuing all development for ATA3219 and ATA3431, including CAR T clinical studies.
Estimated severance and related benefits of $3.0 million, primarily one-time cash charges.
Additional details to be provided in the Q1 2025 10-Q filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.